Session » Muscle Biology, Myositis and Myopathies Poster I

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0167

Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases

1:00PM-3:00PM: Abstract Number: 0180

Alterations of Nutritional Status in Patients with Idiopathic Inflammatory Myopathies and Their Association with Disease-related Features

1:00PM-3:00PM: Abstract Number: 0154

Anti-SMN Autoantibodies in Mixed Connective Tissue Disease Are Associated with a Scleromyositis Phenotype

1:00PM-3:00PM: Abstract Number: 0164

Anti-SSa/SSb and Ro52 Status and Pulmonary Function Tests in Patients with Interstitial Lung Disease and Idiopathic Inflammatory Myopathies

1:00PM-3:00PM: Abstract Number: 0159

B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab

1:00PM-3:00PM: Abstract Number: 0157

Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale

1:00PM-3:00PM: Abstract Number: 0171

Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?

1:00PM-3:00PM: Abstract Number: 0163

Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic

1:00PM-3:00PM: Abstract Number: 0172

Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study

1:00PM-3:00PM: Abstract Number: 0162

Clinical Features Associated with the Presence of anti-SSA/Ro60 Antibodies in anti-Jo-1 Antibody-positive Myositis

1:00PM-3:00PM: Abstract Number: 0169

Comparison of Diagnostic Criteria Sets in Diagnosing Antisynthetase Syndrome

1:00PM-3:00PM: Abstract Number: 0177

COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey

1:00PM-3:00PM: Abstract Number: 0173

Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis

1:00PM-3:00PM: Abstract Number: 0166

Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients

1:00PM-3:00PM: Abstract Number: 0176

Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis

1:00PM-3:00PM: Abstract Number: 0179

Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies

1:00PM-3:00PM: Abstract Number: 0158

Effect of Type I IFN on Mitochondria and Muscle Weakness in Myositis

1:00PM-3:00PM: Abstract Number: 0175

Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies – a Potential Lifesaving Intervention

1:00PM-3:00PM: Abstract Number: 0150

Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis

1:00PM-3:00PM: Abstract Number: 0156

Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database

1:00PM-3:00PM: Abstract Number: 0174

Intra-rater Validation of Calcinosis Durometer Measurements in Juvenile and Adult Dermatomyositis

1:00PM-3:00PM: Abstract Number: 0161

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells

1:00PM-3:00PM: Abstract Number: 0165

Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis

1:00PM-3:00PM: Abstract Number: 0170

Minimal Clinically Important Difference in Myositis Response Criteria

1:00PM-3:00PM: Abstract Number: 0178

Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism

1:00PM-3:00PM: Abstract Number: 0151

Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study

1:00PM-3:00PM: Abstract Number: 0153

Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients

1:00PM-3:00PM: Abstract Number: 0152

Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome

1:00PM-3:00PM: Abstract Number: 0160

Sarcopenia in Myositis Patients: A Marker of Muscle Damage Associated with Myositis Severity and Disability

1:00PM-3:00PM: Abstract Number: 0168

Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)

1:00PM-3:00PM: Abstract Number: 0155

Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].